RARE - Ultragenyx Pharmaceutical GAAP EPS of -$2.33 misses by $0.33 revenue of $100.5M misses by $3.4M

2023-05-04 16:49:46 ET

• Ultragenyx Pharmaceutical press release ( NASDAQ: RARE ): Q1 GAAP EPS of -$2.33 misses by $0.33 .
• Revenue of $100.5M (+25.8% Y/Y) misses by $3.4M .
• First quarter 2023 total revenue of $100.5 million, Crysvita revenue of $76.0 million and Dojolvi revenue of $14.3 million
• Total revenue grew 26% and Crysvita revenue grew 28% versus the first quarter 2022
• Reaffirmed 2023 expected total revenue guidance between $425 million to $450 million vs $434.75M consensus, Crysvita revenue of $325 million to $340 million, and Dojolvi revenue of $65 million to $75 million

For further details see: